Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy

BACKGROUND: (213)Bismuth ((213)Bi, T(1/2) = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing less than 222 MBq (225)Ac (actinium), due to limited av...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Ho Sze, de Blois, Erik, Konijnenberg, Mark W., Morgenstern, Alfred, Bruchertseifer, Frank, Norenberg, Jeffrey P., Verzijlbergen, Fred J., de Jong, Marion, Breeman, Wouter A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843812/
https://www.ncbi.nlm.nih.gov/pubmed/29564386
http://dx.doi.org/10.1186/s41181-016-0014-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843812/
https://www.ncbi.nlm.nih.gov/pubmed/29564386
http://dx.doi.org/10.1186/s41181-016-0014-4

Ejemplares similares